EGFR and neoplasm: Applying these new insights, we improved upon the traditional concepts of ErbB2 targeting by designing and mechanistically dissecting new biparatopic agents that trap ErbB2 in a dimerization-incompetent state thereby entailing the pan-ErbB inhibition in ErbB2-addicted tumours.